butyric acid has been researched along with levofloxacin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alling, T; Bailey, MA; Casey, A; Early, JV; Files, M; Gonzalez Valcarcel, IC; Martinez-Grau, MA; Ollinger, J; Ovechkina, Y; Parish, T; Vieth, M | 1 |
| Cao, Y; Chen, J; Han, Y; Liang, X; Song, M; Xiao, H; Xiao, J; Yang, X; Zhan, M; Zhao, C | 1 |
2 other study(ies) available for butyric acid and levofloxacin
| Article | Year |
|---|---|
Oxadiazoles Have Butyrate-Specific Conditional Activity against Mycobacterium tuberculosis.
Topics: Animals; Antitubercular Agents; Butyric Acid; Cell Survival; Chlorocebus aethiops; Culture Media; Glucose; High-Throughput Screening Assays; Isoniazid; Kanamycin; Levofloxacin; Metabolic Networks and Pathways; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Oxadiazoles; Small Molecule Libraries; Species Specificity; Structure-Activity Relationship; Vero Cells | 2016 |
Dietary 5-demethylnobiletin prevents antibiotic-associated dysbiosis of gut microbiota and damage to the colonic barrier.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Butyric Acid; Cefuroxime; Colon; Dysbiosis; Gastrointestinal Microbiome; Intestinal Diseases; Intestines; Levofloxacin; Mice | 2023 |